almagate has been researched along with Proliferative Vitreoretinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buil-Calvo, JA; Cordero, JA; Evans, JR; Martí-Carvajal, AJ; Martinez-Zapata, MJ; Pijoán, JI; Solà, I | 1 |
| Abdallah, W; Fawzi, AA | 1 |
2 review(s) available for almagate and Proliferative Vitreoretinopathy
| Article | Year |
|---|---|
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Female; Humans; Light Coagulation; Male; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative | 2014 |
Anti-VEGF therapy in proliferative diabetic retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative; Vitreous Body | 2009 |